Dx Deals: Quest Closes PathAI Partial Acquisition and Strategic Alliance
Deal is expected to give the lab giant a big boost in deploying artificial intelligence in the pathology space.
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
Deal is expected to give the lab giant a big boost in deploying artificial intelligence in the pathology space.
Genomics software developer Allelica to collaborate with Taiwanese precision medicine firm to develop a multi-ancestry breast cancer test.
Economic volatility and uncertainty is also making a significant impact on merger and acquisition activity in the diagnostics space.
An effective business case communicates need, benefit, and risks.
Abbott and Roche garnered the lion’s share of new 510(k) lab test approvals in 2022.
There were three notable CDx alliances announced in January 2023, all of which involved cancer-related solutions.
According to a new report, tough macro-economic conditions caused digital health fundraising levels to fall off dramatically in 2022.
Factors to consider when determining if the concierge business model is best for your laboratory.
Deals involving the development and commercialization of new cancer diagnostics and treatments were the most common in December.
Here are what G2 Intelligence considers to be the 10 most significant FDA lab testing clearances of 2022, in rough chronological order.
Here’s an approach to ensure your lab patients have the most positive financial experience possible.